{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:52Z","timestamp":1778711872166,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Research Council","award":["CONICET-PIP0088"],"award-info":[{"award-number":["CONICET-PIP0088"]}]},{"name":"National Agency of Scientific and Technical Promotion","award":["SECyT-PICT 0330"],"award-info":[{"award-number":["SECyT-PICT 0330"]}]},{"name":"National Institute of Cancer (INC-493)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T02:48:50Z","timestamp":1462934930000},"page":"129-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome"],"prefix":"10.1016","volume":"59","author":[{"given":"Natalia","family":"Weich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Giere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Fundia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.05.007_bb0005","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0010","doi-asserted-by":"crossref","first-page":"27535","DOI":"10.3390\/ijms161126049","article-title":"DNA repair-a double-edged sword in the genomic stability of cancer cells-the case of chronic myeloid leukemia","volume":"16","author":"Pawlowska","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0015","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2008-07-169110","article-title":"Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia","volume":"113","author":"Kim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0020","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1007\/s13277-014-1810-7","article-title":"Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia","volume":"35","author":"He","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0025","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia","author":"Soverini","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0030","doi-asserted-by":"crossref","first-page":"36269","DOI":"10.18632\/oncotarget.5915","article-title":"Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia","volume":"6","author":"Bruzzoni-Giovanelli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","article-title":"BCR-ABL mutations in chronic myeloid leukemia","volume":"25","author":"Ernst","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/10428190701858823","article-title":"Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia","volume":"49","author":"Clark","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PPO.0b013e318237e5b7","article-title":"Development of an effective therapy for chronic myelogenous leukemia","volume":"17","author":"Woessner","year":"2011","journal-title":"Cancer J."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0055","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0060","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","article-title":"Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0065","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0070","first-page":"57","article-title":"Uncovering the role of p53 splice variants in human malignancy: a clinical perspective","volume":"7","author":"Surget","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0080","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1038\/onc.2015.25","article-title":"p53, a translational regulator: contribution to its tumour-suppressor activity","volume":"34","author":"Marcel","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/BJ20150517","article-title":"Regulation of the p53 response and its relationship to cancer","volume":"469","author":"Meek","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0095","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","article-title":"Two polymorphic variants of wild-type p53 differ biochemically and biologically","volume":"19","author":"Thomas","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","article-title":"The codon 72 polymorphic variants of p53 have markedly different apoptotic potential","volume":"33","author":"Dumont","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1582-4934.2008.00634.x","article-title":"Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment","volume":"13","author":"Hrstka","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2584","article-title":"p53 polymorphisms: cancer implications","volume":"9","author":"Whibley","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0115","first-page":"868","article-title":"TP53 codon 72 polymorphism in patients with chronic myeloid leukemia","volume":"89","author":"Bergamaschi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0120","first-page":"316","article-title":"TP53 codon 72 polymorphism and risk of chronic myeloid leukemia","volume":"13","author":"Sailaja","year":"2009","journal-title":"Gene Ther. Mol. Biol."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biopha.2012.11.004","article-title":"Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia","volume":"67","author":"Camelo-Santos","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/mc.22061","article-title":"MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib","volume":"53","author":"Liu","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0135","doi-asserted-by":"crossref","first-page":"e1588","DOI":"10.1097\/MD.0000000000001588","article-title":"The role of TP53 gene codon 72 polymorphism in leukemia: a PRISMA-compliant systematic review and meta-analysis","volume":"94","author":"Ruan","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0140","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0145","first-page":"8","article-title":"Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer","volume":"29","author":"Costa","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045820","article-title":"p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis","volume":"7","author":"Weng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25710","article-title":"Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies","volume":"129","author":"Francisco","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2004.11.025","article-title":"The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece","volume":"222","author":"Kalemi","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0165","first-page":"711","article-title":"P53 codon 72 polymorphism in breast cancer","volume":"10","author":"Buyru","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cdp.2006.09.007","article-title":"Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk","volume":"30","author":"Damin","year":"2006","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0175","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/bcr1780","article-title":"Implication of BRCA2 - 26G>A 50 untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism","volume":"9","author":"Gochhait","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcmd.2016.05.007_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2006.12.006","article-title":"An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran","volume":"56","author":"Nadji","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ijc.11548","article-title":"p53 polymorphic variants at codon 72 exert different effects on cell cycle progression","volume":"108","author":"Pim","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0190","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1038\/sj.onc.1209405","article-title":"Trp53-dependent DNA-repair is affected by the codon 72 polymorphism","volume":"25","author":"Siddique","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2016.05.007_bb0195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"2","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:26Z","timestamp":1761049946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":39,"alternative-id":["S1079979616300559"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.05.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}